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Reactivation of telomerase has been implicated in human tumorigenesis, but the underlying
mechanisms remain poorly understood. Here we report the presence of recurrent somatic
mutations in the TERT promoter in cancers of the central nervous system (43%), bladder
(59%), thyroid (follicular cell-derived, 10%) and skin (melanoma, 29%). In thyroid cancers,
the presence of TERT promoter mutations (when occurring together with BRAF mutations) is
significantly associated with higher TERT mRNA expression, and in glioblastoma we find a
trend for increased telomerase expression in cases harbouring TERT promoter mutations.
Both in thyroid cancers and glioblastoma, TERT promoter mutations are significantly
associated with older age of the patients. Our results show that TERT promoter mutations are
relatively frequent in specific types of human cancers, where they lead to enhanced
expression of telomerase.
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R
eactivation or re-expression of telomerase is referred to be a
widespread feature in human cancers, although the genetic
basis remains poorly understood in many cancer types.
Somatic mutations in the coding region of TERT (human
telomerase reverse transcriptase) are infrequent in human
tumours, but germline and somatic mutations in TERT promoter
were recently found in a high percentage of human melanomas
and human cancer cell lines1,2. Such mutations occurred in two
hotspot positions, located  124 and  146 bp upstream from
the ATG start site ( 124 G4A and  146 G4A, C4T on
opposite strand) and conferred enhanced TERT promoter
activity1,2, by putatively generating a consensus binding site
(GGAA) for ETS transcription factors within the TERT promoter
region1,2.
Our aim was to investigate whether the aforementioned TERT
promoter mutations were present in cancer types other than
melanoma, having for that matter screened 741 primary tumours
from the thyroid, kidney, bladder, gastrointestinal stromal
tumour (GIST), adrenal medulla (phaeochromocytomas) and
central nervous system (CNS). Besides skin melanoma, we have
also included ocular melanoma (not studied in the previous
reports), benign lesions of the thyroid and skin and 58 human
cancer-derived cell lines. Our results highlight TERT promoter
mutations as frequent events in specific types of human cancers.
Results
TERT mutations in tumours and cell lines. Overall, TERT
promoter mutations were found in 142 (19%) human tumour
samples (Table 1; Fig. 1a) and 14 (24%) human cell lines (Fig. 1b;
Supplementary Tables S1 and S2). The  124-bp mutation was
the most frequent, being present in 99 cases, whereas the  146-
bp mutation was present in 43 cases. The  124 G4A and  146
G4A mutations were found in a mutually exclusive fashion. Two
tandem GG4AA mutations at positions  124/ 125 and
 138/ 139 bp were observed in one cell line each
(Supplementary Fig. S1 and Supplementary Table S1). TERT
promoter mutations were not detected in normal thyroid tissue
nor in benign lesions (nevi, thyroiditis, goitres and adenomas).
No mutations were detected in 26 kidney cancers, 17 phaeo-
chromocytomas and 36 GISTs.
TERT mutations in melanoma. We have analysed both skin and
ocular melanomas, a type of melanoma that was not previously
studied1,2. TERT mutations were present in 16 out of 56 (29%)
skin melanomas, but absent in the 25 ocular melanomas
(Table 1). All the four skin melanoma-derived cell lines but
none of the six ocular melanoma-derived cell lines harboured
TERT mutations (Fig. 1b and Supplementary Table S1). Ten out
of 16 (63%) skin melanomas with TERT mutation also harboured
the BRAFV600E mutation, whereas the BRAF mutation was
present in 9 out of 38 (24%) melanomas without TERT mutation
(P¼ 0.01, Fisher’s exact test, two-sided) (Supplementary Fig. S2
and Supplementary Table S3).
TERT mutations in CNS tumours. In CNS tumours, TERT
promoter mutations were found in 43% (51/118) of all cases
with an equal prevalence of both mutations (Table 1 and
Supplementary Table S4). The frequency of TERT mutations was
different according to the tumour histology and grade (Fig. 1c):
although pilocytic astrocytomas (World Health Organization
(WHO) grade 1) and diffuse astrocytoma (WHO grade 2) showed
a lower frequency of mutations (8% and 15%, respectively),
the most aggressive form, glioblastoma multiforme (GBM;
WHO grade 4), present the highest frequency of TERT mutations
(62%). Oligodendrogliomas (WHO grade 2) and anaplastic
oligodendrogliomas (WHO grade 3) also harboured a high fre-
quency of TERT mutations (45% and 54%, respectively).
The presence of TERT mutations was significantly associated
with a higher mean age at diagnosis (Supplementary Table S5) in
CNS patients as a whole (Po0.0001; Mann–Whitney test, two-
tailed) and also in GBM patients only (P¼ 0.0247; Mann–
Whitney test, two-tailed); in oligodendroglioma patients, we
found the same trend, although not statistically significant
(P¼ 0.0709; Mann–Whitney test, two-tailed). In addition, we
observed that, in a subset of 14 GBM (8 TERT wild-type tumours
and 6 TERT-mutated tumours), the tumours with TERT
mutations showed a trend to increased immunohistochemistry
(IHC) expression of telomerase, although this difference was
not statistically significant (P¼ 0.4250; Mann–Whitney test,
two-tailed) (Fig. 2).
TERT mutations in thyroid cancer. We analysed a large series of
follicular cell-derived thyroid samples including normal thyroid
(n¼ 27), benign (n¼ 81) and malignant lesions (n¼ 263)
(Table 1 and Supplementary Table S6). TERT mutations were
only detected in malignant tumours (10%) (Fig. 1d), namely in
Table 1 | Prevalence of TERT promoter recurrent mutations
in human cancers.
Organ/tissue Number TERT mutation, N (%)
Melanocytes
Nevi 9 0
Skin melanoma 56 16 (29%)
Ocular melanoma 25 0
CNS
Pilocytic astrocytoma 13 1 (8%)
Diffuse astrocytoma 20 3 (15%)
Oligodendroglioma 22 10 (45%)
Anaplastic oligodendroglioma 24 13 (54%)
Glioblastoma 39 24 (62%)
Thyroid
Benign 81 0
PTC 169 13 (8%)
FTC 64 9 (14%)
PDTC 14 3 (21%)
ATC 16 2 (13%)
MTC 28 0
Bladder
Low grade 21 14 (67%)
High grade 61 34 (56%)
Kidney
CCRCC 12 0
CromRCC 4 0
PRCC 10 0
Adrenal
Phaeochromocytoma 17 0
GI
GIST 36 0
Total 741 142 (19%)
ATC, anaplastic thyroid carcinoma; CCRCC, clear cell renal cell carcinoma; CNS, central nervous
system; CromRCC, chromophobe renal cell carcinoma; FTC, follicular thyroid carcinoma;
GI, gastrointestinal; GIST, gastrointestinal stromal tumour; MTC, medullary thyroid carcinoma;
PDTC, poorly differentiated thyroid carcinoma; PRCC, papillary renal cell carcinoma; PTC,
papillary thyroid carcinoma.
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11% of papillary thyroid carcinomas (PTCs), 14% of follicular
thyroid carcinomas, 21% of poorly differentiated thyroid carci-
nomas and 13% of the anaplastic thyroid carcinomas. Within the
group of PTC, TERT mutations were detected to be associated to
the so-called conventional PTC (cPTC) (11%).The majority of
TERT-mutated thyroid cancers harboured the  124 G4A
mutation (22 out of 27 cases) (Fig. 1d and Supplementary
Table S7). In thyroid cancer patients, TERT mutations were sig-
nificantly associated with guarded prognosis features such as
larger tumours (P¼ 0.008; Mann–Whitney test, two-tailed),
older patients (Po0.0001; Mann–Whitney test, two-tailed)
and male gender (P¼ 0.0312; Fisher’s exact test, two-sided)
(Supplementary Table S5). After histotype stratification, such
correlations were only kept in the group of cPTC where we
also found significant associations with lymph node metastasis
(P¼ 0.0318; Fisher’s exact test, two-sided) and BRAFV600E
mutation (P¼ 0.001; Fisher’s exact test, two-sided)
(Supplementary Fig. S2 and Supplementary Table S8). Accord-
ingly, we verified by quantitative RT-PCR (qPCR) that TERT
mRNA is expressed at variable amounts in thyroid tumours, and
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Figure 1 | Frequency and schematic illustration of TERT promoter mutations in human cancers. Graphics depict the overall frequency of TERT mutations
in the four tumour types where TERT mutations were detected (a) and a bar plot showing the number of cell lines of different origin that harbour
TERT mutations (b). The frequency and type of TERT mutations in different histological subtypes of CNS (c), thyroid (d) and bladder (e) tumours is also
shown. A, diffuse astrocytoma; AO, anaplastic oligodendroglioma; ATC, anaplastic thyroid carcinoma; GB-glioblastoma; FTC, follicular thyroid carcinoma;
O, oligodendroglioma; PA, pilocytic astrocytoma; PDTC, poorly differentiated thyroid carcinoma.
a b
c P= 0.42510
8
6
4
2
0
TERT wt
(n=8)
TERT mutation
(n=6)
T
E
R
T
 e
xp
re
ss
io
n
le
ve
l (
A
U
)
Figure 2 | IHC for TERT in two glioblastomas. (a)A tumour without TERT expression and without TERT mutation. (b) A tumour with positive staining both
in nucleus and cytoplasm that also harboured a TERT mutation. The graph (c) displays quantification of TERT nuclear expression level (IHC) in
glioblastomas with and without TERT mutation. We have measured the extent (o25%, 25–50%, 50–75% and 475%) and the intensity (absent, faint,
moderate or strong) of TERT nuclear staining in 14 glioblastomas (eight TERT wild type and six TERT mutant). The scoring was performed by two
independent observers and is the product of extent and intensity of the staining (Methods). Scale bar, 200mm. There is a trend to higher TERT expression
in TERT-mutated gliomas, although the difference was not statistically significant (P¼0.4250; Mann–Whitney test, two-tailed). Bars represent s.e.m.
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the ones with coexistent TERT and BRAF mutations showed the
highest levels of TERT mRNA expression (P¼ 0.0001, unpaired
t-test; Fig. 3).
TERT mutations in bladder cancer. In bladder cancer, TERT
mutations were frequently detected (48/82; 59%) both in low-
grade tumours (14/21; 67%) and high-grade tumours (34/61;
56%) (Table 1 and Fig. 1e; Supplementary Table S9). The  124
G4A mutation was present in 30 cases, whereas the  146 G4A
was found in 18 cases. No association was found between the
presence of the mutation and the age of the patients.
No mutations were detected in 26 kidney cancers, 17
phaeochromocytoma and 36 GISTs (Supplementary Tables S10,
S11 and S12, respectively).
Discussion
Recent findings have described that TERT promoter mutations
arise as a novel mechanism of telomerase reactivation/expression
in human cancers1,2. In this work, we report for the first time the
presence of these mutations in different histotypes of thyroid
cancer, and our results validate the findings reported by others in
melanoma, bladder and gliomas1–3. Furthermore, we present for
the first time evidence showing that TERT promoter mutations
are significantly associated with increased TERT mRNA
expression in thyroid cancers. We also found a trend for
increased telomerase expression in cases of GBM harbouring
TERT promoter mutations. In thyroid cancers, TERT mRNA was
particularly high in cases harbouring both TERT and BRAF
mutations.
The location of these mutations in the TERT promoter, rather
than the coding region of the gene, creating additional binding
sites for transcription factors, represents also a novel mechanism
of genetic activation in cancer.
The frequency of TERT mutations we detected in skin
melanomas is similar to that reported by Horn et al.1 in
primary melanomas (33%), but lower than the frequency found
by the same authors in metastatic melanomas (85%) and by
Huang et al.2 in a series of 70 melanomas and short-term
cultures1,2. In our series, we have analysed few metastatic
melanomas that did not show a significantly higher percentage
of TERT mutations. As our series is too small to allow a
conclusion, it remains to be verified if there is an increased
frequency of TERT mutations in metastatic melanomas, as
suggested by previous reports1,2.
We have confirmed, in skin melanomas, the significant
association between TERT and BRAF mutations, as previously
advanced by Horn et al.1, which we now also demonstrate in
thyroid cancers. Interestingly, in benign nevi, which frequently
harbour BRAF mutations, we did not detect TERT mutations.
This finding, together with the high frequency of TERT mutations
in metastatic melanomas1, suggests that, although BRAF
mutations are thought to be an early event in melanoma
genesis, TERT mutations may occur at a later stage.
No TERT promoter mutations were found in ocular melano-
mas, which, at variance with skin melanomas, harbour GNAQ
mutations instead of BRAF mutations4,5. Our results further
support the assumption that ocular melanomas result from
different etiopathogenic mechanism than skin melanomas5,6.
Our data on CNS tumours indicate that TERT promoter
mutations are frequent events in gliomas, particularly in GBM
where the highest mutation frequency was found. It has been
shown that TERT mutations conferred enhanced TERT promoter
activity in vitro1,2; our findings fit with this assumption because
we observed that GBM with TERT promoter mutations appear to
display increased telomerase expression, despite the limited
sensitivity of IHC and the low number of cases analysed. Our
results are also in concordance with those of Lotsch et al.7 who
reported that 60% of GBMs were positive for TERT mRNA and
telomerase activity7. It will be interesting to assess whether the
GBM positive for telomerase activity described by Lotsch et al.7
also harbour TERT promoter mutations. Our findings also
indicate that TERT mutations are associated with older patients,
in accordance with a recent report3. The high frequency of TERT
mutations in CNS tumours, particularly in intermediate and
high-grade tumours, opens a window for new approaches in the
therapy of CNS tumours.
In thyroid cancer, TERT mutations were only found in
follicular cell-derived cancers (PTC, follicular thyroid carcinoma,
poorly differentiated thyroid carcinoma and anaplastic thyroid
carcinoma). No mutations were detected in medullary thyroid
carcinomas, as described by Killela et al.3, nor in normal thyroid
and benign lesions, such as goitre, adenomas or thyroiditis; this
finding fits with previous studies that reported telomerase
expression in malignant lesions and not in normal tissue or
hyperplastic lesions8,9. TERT mutations were associated with
clinicopathological features (older age, increased tumour size and
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Figure 3 | Quantification of TERT mRNA expression level in thyroid tumours. We have performed qPCR in normal thyroid tissue (N), a pool of
mRNA of nine normal thyroids (pool N) and thyroid tumours with different genetic backgrounds: without known genetic alterations (wt), with BRAF
mutation (B), with RET rearrangement (RET), with RAS mutation (R), with TERT mutation (T), with TERT and BRAF mutations (BT) or with RAS and TERT
mutations (RT). (a) Each bar represents TERT mRNA expression in an individual tumour measured in triplicate. TERT mRNA levels were normalized
against TBP mRNA levels. (b) Quantification of TERT mRNA mean expression level in thyroid tumours with and without TERT mutation. Error bars represent
s.e.m. The difference is statistically significant (Po0.0001, unpaired t-test).
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male gender), but, after histotype stratification, these associations
were only maintained in cPTC. Studies in larger series will be
necessary to clarify these associations. In cPTC, TERT mutations
were associated with BRAF mutation, highlighting the coexistence
of activation of BRAF and TERT, previously reported in
melanoma1 (Supplementary Fig. S2). Our results reinforce the
hypothesis of a link between BRAF activation and telomerase
expression, which can be mediated by transcription factors
binding to the newly created consensus binding sites, as
previously advanced by Horn et al.1. Both in thyroid carcinoma
and melanoma, it seems that a ‘background’ status of activated
BRAF enhances the effects of TERT promoter mutation. Our
results in TERT mRNA expression strengthen this assumption,
showing, for the first time, an increased TERT expression in
tumours harbouring BRAF and TERT mutation (Fig. 3). Further
observational and mechanistic studies are needed to clarify these
points.
TERT alterations seem to constitute an early and frequent
event in bladder cancer. These findings fit with the high
prevalence of telomerase activity previously described in bladder
tumours10. The recurrent hotspot mutations in TERT were
advanced to be, in melanomas, induced by ultraviolet radiation2.
Bladder is a target for several chemical carcinogens; it remains to
be found whether TERT mutations can also result from the action
of such agents. The identification of TERT mutations in urine
may provide a biomarker for early diagnosis and monitoring of
bladder cancer.
No TERT mutations were detected in kidney cancers, nor in 17
phaeochromocytoma and 36 GISTs. The underlying reasons for
the tissue specificity of TERT mutations remain to be clarified.
We can hypothesize that TERT mutations can be present in two
settings. As described by Killela et al.3, TERT mutations can be
relevant in tissues with relative low rates of self-renewal, which
fits with our findings in follicular cell-derived thyroid cancer and
gliomas where they are associated with the older age of the
patients. On the other hand, these mutations can also result from
environmental factors such as ultraviolet radiation and chemical
carcinogens as suggested by their high frequency in melanoma,
bladder and tongue1–3. In summary, our data identify TERT
mutations as common events in human cancers and support the
assumption that TERT promoter mutations may be one of the
mechanisms that underlies telomerase reactivation in several
types of human tumours.
Methods
Human cancer samples. All the procedures described in this study were in
accordance with national and institutional ethical standards and previously
approved by Local Ethical Review Committees. According to Portuguese law,
informed consent is not required for retrospective studies.
Formalin-fixed, paraffin-embedded tissues from nine cases of sporadic nevi, 56
cases of sporadic skin melanomas and 25 cases of ocular melanoma were retrieved
from the files of the Hospital S. João (HSJ)/Medical Faculty of Porto (FMUP),
Porto, Portugal, the Department of Pathology of HSJ and the Department of
Pathology of Hospital S. Marcos (HSM), Braga, Portugal. Clinicopathological and
follow-up data were retrieved from the files of the Department of Pathology,
Department of Dermatology and Oncology Registry of HSJ and Department of
Pathology of HSM, and from RORENO (Oncology Registry of North Region). All
skin melanoma cases were re-evaluated and staged according to the seventh edition
of the American Joint Committee on Cancer11. The overall female:male ratio was
1.2:1. The mean age of the patients was 58 years for females (s.d.±17.6), with a
range from 9 to 94 years, and 62 years for males (s.d.±13.1), with a range from 33
to 79 years.
Follow-up data were available for 53 patients, including the diagnosis of
metastases, through the evaluation of the patients or direct interview with their
relatives and by review of in-hospital patient files/RORENO. The mean follow-up
time of patients was 41 months (range 1–170). During follow-up, 5 (9%) patients
developed (lymph node, liver or brain) metastases and 8 (15%) patients died due to
malignant melanoma. The remaining patients were alive and without evidence of
melanoma recurrence at the last follow-up. Additional information regarding the
melanoma subtype, age, gender, thickness and molecular analysis of TERT, BRAF
and NRAS is compiled in Supplementary Table S3.
Formalin-fixed, paraffin-embedded tissues from 372 tumours and tumour-like
lesions of the thyroid and 27 normal thyroids were collected from the files of
IPATIMUP, HSJ/FMUP and the Portuguese Institute of Oncology, Coimbra,
Portugal. The histology of all tumour samples was revised, and the final
classification was made according to the WHO criteria12. In Supplementary Tables
S6 and S7, we have summarized the information regarding histological
classification of the lesions, gender, mean age of the patients, molecular data and
the size of the tumours.
Representative formalin-fixed paraffin-embedded samples from 118 gliomas
were retrieved from pathology archives of the Department of Pathology of
HSJ/FMUP and the Department of Pathology of HSM, Braga, Portugal. The
tumours were reviewed and classified according to the WHO classification of CNS
tumours (2007) (ref. 13,14). This cohort includes lesions that were classified as
pilocytic astrocytoma (n¼ 13), astrocytoma grade 2 (n¼ 20), oligodendroglioma
(n¼ 22), anaplastic oligodendroglioma (n¼ 24) and glioblastoma (n¼ 39). Further
information regarding the CNS cases is available in Supplementary Table S4.
Formalin-fixed, paraffin-embedded tissues were collected from 82 patients with
non-muscle invasive bladder cancer who underwent transurethral resection of the
bladder malignant tumours in the Portuguese Institute of Oncology, Porto.
Haematoxylin–eosin-stained sections were reviewed according to the standard
histopathological examination by two independent pathologists. Staging and
grading were conducted according to the American Joint Committee on Cancer11,
and the 2004 WHO classification system15. Supplementary Table S9 summarizes
the clinicopathological parameters.
Formalin-fixed, paraffin-embedded tissues from 26 kidney cancers were
collected from the HSJ/FMUP. Cases were classified as clear cell renal cell
carcinoma (n¼ 12), chromophobe renal cell carcinoma (n¼ 4) and papillary renal
cell carcinoma (n¼ 10). Information addressing the diagnosis, age, gender, nuclear
grade and staging is obtainable in Supplementary Table S10.
Formalin-fixed, paraffin-embedded tissues from 17 pheochromocytomas were
collected from the HSJ/FMUP and IPATIMUP, Porto, Portugal. Supplementary
Table S11 summarizes the clinicopathological parameters.
Formalin-fixed, paraffin-embedded tissues from 36 GIST were collected from
the HSJ/FMUP and IPATIMUP, Porto, Portugal. Tumours were classified
according to the WHO pathological classification16, and the parameters analysed in
each case included: age, gender and tumour size. These data and the molecular
characterization of these tumours can be observed in Supplementary Table S12.
Cell lines. DNA from 58 cell lines deposited in IPATIMUP cell line bank was
retrieved. All the cell lines were authenticated using DNA profile analysis, obtained
with the PowerPlex 16 system (Promega, Madison, USA), according to the DNA
profiles available in American Type Culture Collection and Health Science
Research Resource Bank.
DNA extraction. DNA from formalin-fixed, paraffin-embedded tissues was
retrieved from 10-mm cuts after careful microdissection. DNA extraction was
performed using the Ultraprep Tissue DNA Kit (AHN Biotechnologie, Nordhau-
sen, Germany) following the manufacturer’s instructions.
RNA extraction. Total RNA was extracted from frozen thyroid tumours (n¼ 24)
and normal tissue specimens (n¼ 3) using a Trizol commercial kit (Life Tech-
nologies, GIBCO BRL, Carlsbad, CA) according to the manufacturer’s protocol.
RNA was quantified spectrophotometrically, and its quality was checked by ana-
lysis of 260/280Zm and 260/230Zm ratios.
PCR and Sanger sequencing. Coding regions of BRAF, GNAQ HRAS, NRAS,
cKIT and PDGFR were screened for mutations in DNA extracted from paraffin
blocks using PCR and Sanger sequencing. The genetic characterization of part of
the tumours had already been previously reported. For information on primers and
PCR conditions, see refs 5,17,18. To screen for TERT promoter mutations, we
analysed the hotspots previously identified by PCR followed by Sanger sequencing.
TERT promoter mutation analysis was performed with the pair of primers
FwTERT: 50-CAGCGCTGCCTGAAACTC-30 and RwTERT: 50-GTCCTGCCCC
TTCACCTT-30 . Amplification of genomic DNA (25–100 ng) was performed by
PCR using the Qiagen Multiplex PCR kit (Qiagen, Hilden, Germany) according to
the manufacturer’s instructions. Sequencing reaction was performed with the ABI
Prism BigDye Terminator Kit (Perkin-Elmer, Foster City, CA), and the fragments
were run in an ABI prism 3100 Genetic Analyser (Perkin-Elmer). The sequencing
reaction was performed in a forward direction, and an independent PCR
amplification/sequencing, both in a forward and reverse direction, was performed
in positive samples or samples that were inconclusive.
Quantitative RT-PCR. qPCR for human TERT was performed in 28 thyroid
samples, 24 tumours and 3 normal tissue specimens. We also included a normal
reference that was produced by pooling RNAs from nine samples of normal
thyroid tissue19.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms3185 ARTICLE
NATURE COMMUNICATIONS | 4:2185 | DOI: 10.1038/ncomms3185 | www.nature.com/naturecommunications 5
& 2013 Macmillan Publishers Limited. All rights reserved.
For cDNA preparation, 1 mg of total RNA was reverse transcribed using the
RevertAid first strand cDNA synthesis kit (Fermentas, Burlington, ON, Canada).
Reverse transcription products were amplified for the TERT by qPCR (IDT; no.
HS.PT.56a.40988589) using TaqMan PCR Master Mix (Applied Biosystems, Foster
City, CA, USA) with TBP gene (TATA-binding protein) as endogenous control
(Applied Biosystems; no. 4326322E-0705006). The ABI PRISM 7500 Fast Sequence
Detection System (Applied Biosystems) was used to detect the amplification level
and was programmed to an initial step of 2 min at 50 C, 10 min at 95 C, followed
by 45 cycles of 95 C for 15 s and 60 C for 1 min. TBP and TERT amplifications
were done in triplicate using 1 ml of cDNA (B50 ng) for each sample. The relative
quantification of target genes was determined using the DDCT method, which was
previously validated by Livak’s Linear Regression Method (slope¼ 0.0696)
(Sequence Detector User Bulletin 2; Applied Biosystems).
Immunohistochemistry. IHC for telomerase was performed in representative
tumour tissue sections of 14 glioblastomas. Briefly, deparaffinized and rehydrated
sections were subjected to microwave treatment in 10 mM sodium citrate buffer,
pH 6.0, for antigen retrieval. The sections were incubated overnight at 4 C in a
humidified chamber with the primary antibody telomerase (polyclonal, rabbit,
1:500) from Rockland Immunochemicals Inc., Gilbertsville, PA. The detection was
performed with a labelled streptavidin–biotin immunoperoxidase detection system
(Thermo Scientific/Lab Vision, Fremont, USA), and the immunohistochemical
staining was developed with 3,30-diaminobenzidine substrate. Omission of the
primary antibody incubation was used as negative control. Previously tested liver
cancer case was used as positive control. IHC evaluation was performed inde-
pendently by two observers (V.M. and J.L.). An IHC score was established, which
corresponded to the product of the intensity of expression (absent¼ 0, faint¼ 1,
moderate¼ 2 and strong¼ 3) with the tumour extent of protein expression
(0–25%¼ 0, 26–50%¼ 1, 51–75%¼ 2 and 475%¼ 3) (ref. 6).
Statistical analysis. Statistical analysis was conducted with StatView for Win-
dows, version 5.0 (SAS Institute, Cary, NC). The results are expressed as a per-
centage or mean±s.d. Statistical analysis was performed both on the whole series
and considering the different groups of lesions. For the analysis of the relationship
between patients’ age, tumour size and TERT status of the tumours, we used the
unpaired t-test, Mann–Whitney test and analysis of variance. Fisher’s exact test was
used in the statistical analysis of the other parameters. Graphs and figures were
done in GraphPad v6.0. Results were considered statistically significant if Po0.05.
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